India
/
Pharma
/
NSEI:BLISSGVS

Bliss GVS Pharma Full Year 2025 Earnings: EPS: ₹8.02 (vs ₹7.23 in FY 2024)

Simply Wall St

May 14, 2025

Bliss GVS Pharma (NSE:BLISSGVS) Full Year 2025 Results

Key Financial Results

Revenue: ₹8.46b (up 9.9% from FY 2024).
Net income: ₹843.0m (up 12% from FY 2024).
Profit margin: 10.0% (in line with FY 2024).
EPS: ₹8.02 (up from ₹7.23 in FY 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

earnings-and-revenue-history — NSEI:BLISSGVS Earnings and Revenue History May 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bliss GVS Pharma shares are up 4.4% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Bliss GVS Pharma that you should be aware of.

If you're looking to trade Bliss GVS Pharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Bliss GVS Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.